Paxlovid^® is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19.³

When administered within 5 days of symptom onset, Paxlovid^® can potentially reduce risk of progression to severe COVID-19 in eligible high-risk adult patients.^3,4†

Order Paxlovid^® stock to your pharmacy today to avoid treatment delays.

Commercial stock of Paxlovid^® is now available for order through Pfizer, via your Alliance Healthcare account. 

• Orders can be placed using PIP code 435-2712 through your PMR system, the Alliance Healthcare website, or by calling Alliance Healthcare directly. Please note that this is a new PIP code effective from 1^st May 2025.
• Paxlovid^® is available to order at NHS list price for a pack of 30 tablets. 
• Delivery: Orders are delivered twice daily by Alliance Healthcare.
• Contact for Queries: Should you require any further information, in the first instance, please speak to your Alliance Healthcare branch. 
• Alternatively, contact the Pfizer Sales Order Management and Customer Excellence team on 0345 6088866 or Freephone 0800 032 7907.

^† Trial Data
In the final analysis of the Phase 2/3 EPIC-HR trial, the primary endpoint (the proportion of patients with COVID-19-related hospitalisation or death from any cause through Day 28 in the modified intend-to-treat analysis set [all treated participants with onset of symptoms ≤3 days who had at least one post-baseline visit]) was achieved: Paxlovid^® (n = 671) demonstrated an ~89% relative risk reduction in hospitalisation or death compared with placebo (n = 647) (absolute risk reduction -6.14% [95% CI −8.21 to −4.07]; P < 0.0001). The key secondary endpoint (the primary comparison analysed similarly among patients whose treatment began within 5 days after the onset of Covid-19 signs and symptoms) was also achieved, as Paxlovid^® (n = 977) demonstrated an 86% relative risk reduction in hospitalisation or death compared with placebo (n = 989) (absolute risk reduction -5.64% [95% CI −7.31 to −3.97]; P < 0.0001).⁴ 
The safety profile of Paxlovid^® is based on data from three Phase 2/3 randomised, placebo-controlled trials in adult participants 18 years of age and older. Across the three studies, 3515 participants received a dose of Paxlovid^® and 2585 participants received a dose of placebo. The most common adverse reactions (≥1% incidence in the Paxlovid group and occurring at a greater frequency than in the placebo group) were dysgeusia (5.9% and 0.4%, respectively) and diarrhoea (2.9% and 1.9%, respectively).³   In addition to the above adverse events, the SmPC also reports nausea and headache as common adverse events.³Anaphylaxis, hypersensitivity reactions and serious skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome) have been reported with Paxlovid^®. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue Paxlovid and initiate appropriate medications and/or supportive care. 
Please refer to the Summary of Product Characteristics for the full list of adverse events.

Community pharmacists are eligible to provide COVID-19 LFD tests to eligible high-risk patients for free through the NHS.^5,6

Financial compensation is available for community pharmacists.⁶

Learn more about the NHS LFD Supply Service here*

Patients with risk factors for severe COVID-19 may be hospitalised and can die.^10,12 These patients need to take rapid action upon confirmation of a positive diagnostic COVID-19 test.^7,8

High-risk conditions^¶ include:^9,10

• Immune-mediated inflammatory diseases
• Immune deficiencies
• HIV/AIDS
• Solid organ cancer
• Liver disease^‡
• Renal disease^‡
• Down’s syndrome or other genetic disorders
• Haematological diseases and HSCT recipients
• Neurological disorders
• Respiratory conditions

COVID-19 is an ongoing burden on healthcare systems.¹¹ Patients with COVID-19 occupied almost 300,000 bed-days in a single year across NHS England.¹²
Early treatment can potentially reduce the risk of progression to severe COVID-19 compared to no treatment, reducing the risk of hospitalisation and death.^4,13

Watch insights videos from KOL discuss importance of managing high-risk patients